GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagenic Therapeutics Inc (NAS:PTIX) » Definitions » E10

PTIX (Protagenic Therapeutics) E10 : $-42.36 (As of Sep. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Protagenic Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Protagenic Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was $-0.140. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-42.36 for the trailing ten years ended in Sep. 2024.

During the past 3 years, the average E10 Growth Rate was 91.20% per year. During the past 5 years, the average E10 Growth Rate was 81.30% per year. During the past 10 years, the average E10 Growth Rate was 54.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Protagenic Therapeutics was 91.20% per year. The lowest was -15.60% per year. And the median was 19.60% per year.

As of today (2025-03-04), Protagenic Therapeutics's current stock price is $0.3679. Protagenic Therapeutics's E10 for the quarter that ended in Sep. 2024 was $-42.36. Protagenic Therapeutics's Shiller PE Ratio of today is .


Protagenic Therapeutics E10 Historical Data

The historical data trend for Protagenic Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protagenic Therapeutics E10 Chart

Protagenic Therapeutics Annual Data
Trend Jun14 Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -250,760.25 -77,564.88 -29,118.96 -1,477.49 -52.63

Protagenic Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -57.24 -52.63 -46.10 -44.46 -42.36

Competitive Comparison of Protagenic Therapeutics's E10

For the Biotechnology subindustry, Protagenic Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protagenic Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagenic Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Protagenic Therapeutics's Shiller PE Ratio falls into.



Protagenic Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Protagenic Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.14/133.0289*133.0289
=-0.140

Current CPI (Sep. 2024) = 133.0289.

Protagenic Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201412 -20.462 99.070 -27.476
201503 -18.308 99.621 -24.448
201506 -17.231 100.684 -22.767
201509 -20.154 100.392 -26.706
201512 -24.308 99.792 -32.404
201603 -211.320 100.470 -279.800
201606 -0.320 101.688 -0.419
201609 -0.240 101.861 -0.313
201612 -0.217 101.863 -0.283
201703 -0.240 102.862 -0.310
201706 -0.160 103.349 -0.206
201709 -0.160 104.136 -0.204
201712 -0.280 104.011 -0.358
201803 -0.240 105.290 -0.303
201806 -0.280 106.317 -0.350
201809 -0.200 106.507 -0.250
201812 -0.320 105.998 -0.402
201903 -0.240 107.251 -0.298
201906 -0.120 108.070 -0.148
201909 -0.040 108.329 -0.049
201912 -0.280 108.420 -0.344
202003 -0.200 108.902 -0.244
202006 -0.240 108.767 -0.294
202009 -0.400 109.815 -0.485
202012 -0.200 109.897 -0.242
202103 -0.440 111.754 -0.524
202106 -0.440 114.631 -0.511
202109 -0.200 115.734 -0.230
202112 -0.200 117.630 -0.226
202203 -0.320 121.301 -0.351
202206 -0.150 125.017 -0.160
202209 -0.210 125.227 -0.223
202212 -0.140 125.222 -0.149
202303 -0.170 127.348 -0.178
202306 -0.280 128.729 -0.289
202309 -0.320 129.860 -0.328
202312 -0.380 129.419 -0.391
202403 -0.390 131.776 -0.394
202406 -0.360 132.554 -0.361
202409 -0.140 133.029 -0.140

Add all the adjusted EPS together and divide 10 will get our e10.


Protagenic Therapeutics  (NAS:PTIX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Protagenic Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Protagenic Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Protagenic Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
Executives
Alexander K. Arrow officer: Chief Financial Officer PO BOX 3094, REDWOOD CITY CA 94064
Jennifer Buell director 3 FORBES ROAD, LEXINGTON MA 02421
Brian Corvese director C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Robert Benjamin Stein director C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Khalil Barrage director 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Gregory Ekizian director 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Robert Ziroyan officer: COO / Interim President 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Garo H Armen director, 10 percent owner, officer: See Remarks 3 FORBES ROAD, LEXINGTON MA 02421
Edward J Gildea director, officer: Chief Executive Officer C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
David J Horin officer: Chief Financial Officer 1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020
Jonathan Schechter director C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
Nathan Yu-gai Fong officer: Chief Financial Officer THE ORCHARD ENTERPRISES, INC., 23 E. 4TH ST., 3RD FL., NEW YORK NY 10003
Sharon Siegel officer: Chief Marketing Officer C/O ATRINSIC, INC., 469 SEVENTH AVENUE, 10TH FLOOR, NEW YORK NY 10018
Raymond Musci director, officer: Exec VP, Corporate Development C/O BRILLIANT DIGITAL ENTERTAINMENT INC, 6355 TOPANGA CANYON BOULEVARD SUITE 520, WOODLAND HILLS CA 91367